The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.
A unique collaboration between electrical engineers and ophthalmologists solves clinical, computational challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback